Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gunnar Birgegård. (2013) Pharmacological management of essential thrombocythemia. Expert Opinion on Pharmacotherapy 14:10, pages 1295-1306.
Read now
Read now
Hans Carl Hasselbalch. (2011) A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology 4:6, pages 637-655.
Read now
Read now
Aaron Polliack, Koen van Besien & John F. Seymour. (2008) 2007: The year in review for Leukemia and Lymphoma. Leukemia & Lymphoma 49:1, pages 1-3.
Read now
Read now
Ayalew Tefferi. (2006) Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?. Leukemia & Lymphoma 47:9, pages 1724-1725.
Read now
Read now
Articles from other publishers (34)
Volodymyr Shponka, Kathleen Bone, Laila Nomani & Bryan Hunt. (2021) Fine‐needle aspiration diagnosis of clonal extramedullary hematopoiesis in a case of myeloproliferative neoplasm. Diagnostic Cytopathology 50:2.
Crossref
Crossref
Paweł Kopka, Katarzyna Bliźniewska, Paulina Sicińska, Piotr Duchnowicz, Bożena Bukowska, Jacek Treliński & Krzysztof Chojnowski. (2020) Eryptosis in polycythemia vera and essential thrombocythemia*. Postępy Higieny i Medycyny Doświadczalnej 74, pages 69-76.
Crossref
Crossref
Jan Jacques Michiels & Hendrik De Raeve. (2019) The PVSG/WHO versus the Rotterdam European clinical, molecular and pathological diagnostic criteria for the classification of myeloproliferative disorders and myeloproliferative neoplasms (MPD/MPN): From Dameshek to Georgii, Vainchenker and Michiels 1950-2018. International Journal of Bone Marrow Research, pages 027-050.
Crossref
Crossref
Ivy Altomare & Craig M. Kessler. 2019. Consultative Hemostasis and Thrombosis. Consultative Hemostasis and Thrombosis
346
373
.
Hans Michael Kvasnicka. 2016. Managing Myeloproliferative Neoplasms. Managing Myeloproliferative Neoplasms
22
36
.
Gunnar Birgegård. (2015) Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology 6:3, pages 142-156.
Crossref
Crossref
Srdan VerstovsekHans Carl Hasselbalch. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment
86
102
.
Wojciech Gorczyca. 2014. Atlas of Differential Diagnosis in Neoplastic Hematopathology, Third Edition. Atlas of Differential Diagnosis in Neoplastic Hematopathology, Third Edition
517
531
.
Hans Michael Kvasnicka. (2013) WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. Current Hematologic Malignancy Reports 8:4, pages 333-341.
Crossref
Crossref
Jamie Koprivnikar & Craig M. Kessler. 2013. Consultative Hemostasis and Thrombosis. Consultative Hemostasis and Thrombosis
298
323
.
Vibe Skov, Mads Thomassen, Caroline H. Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse, Hans Carl Hasselbalch & Thomas Stauffer Larsen. (2012) Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology 40:9, pages 771-780.e19.
Crossref
Crossref
HM Kvasnicka. 2011. Blood and Bone Marrow Pathology. Blood and Bone Marrow Pathology
347
359
.
Maud Brousseau, Elsa Parot‐Schinkel, Marie‐Pierre Moles, Françoise Boyer, Mathilde Hunault & Marie‐Christine Rousselet. (2010) Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 56:6, pages 758-767.
Crossref
Crossref
Hans Michael Kvasnicka & Juergen Thiele. (2009) Prodromal myeloproliferative neoplasms: The 2008 WHO classification. American Journal of Hematology 85:1, pages 62-69.
Crossref
Crossref
Ayalew Tefferi, Radek Skoda & James W. Vardiman. (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nature Reviews Clinical Oncology 6:11, pages 627-637.
Crossref
Crossref
Juergen Thiele. (2009) Philadelphia Chromosome–Negative Chronic Myeloproliferative Disease. American Journal of Clinical Pathology 132:2, pages 261-280.
Crossref
Crossref
Hans Michael Kvasnicka & Juergen Thiele. (2009) Diagnosis of chronic myeloproliferative neoplasms with special emphasis on early stages. Diagnostic Histopathology 15:3, pages 125-133.
Crossref
Crossref
Hans Carl Hasselbalch. (2009) Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Leukemia Research 33:1, pages 11-18.
Crossref
Crossref
Jennifer J. Clark, Jason N. Berman & A. Thomas Look. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
331
402
.
. 2008. Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies. Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies
125
242
.
D Westerman & S Juneja. (2007) Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al.. Leukemia 22:4, pages 864-865.
Crossref
Crossref
THOMAS STAUFFER LARSEN, HANS CARL HASSELBALCH, NIELS PALLISGAARD & MICHAEL BOE MØLLER. (2007) Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. APMIS 115:11, pages 1267-1273.
Crossref
Crossref
Juergen Thiele, Attilio Orazi & Hans Kvasnicka. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
19
50
.
Ayalew TefferiJuergen ThieleAttilio OraziHans Michael KvasnickaTiziano BarbuiCurtis A. HansonGiovanni BarosiSrdan VerstovsekGunnar BirgegardRuben MesaJohn T. ReillyHeinz GisslingerAlessandro M. VannucchiFrancisco CervantesGuido FinazziRonald HoffmanD. Gary GillilandClara D. BloomfieldJames W. Vardiman. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:4, pages 1092-1097.
Crossref
Crossref
Jan Jacques Michiels, Hendrik De Raeve, Konnie Hebeda, King H. Lam, Zwi Berneman, Wilfried Schroyens & Jiri Schwarz. (2007) WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leukemia Research 31:8, pages 1031-1038.
Crossref
Crossref
Matthaios Speletas, Eirini Katodritou, Chrisoula Daiou, Eudokia Mandala, Emmanouil Papadakis, Anna Kioumi, Konstantinos Ritis & Ioannis Korantzis. (2007) Correlations of JAK2–V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leukemia Research 31:8, pages 1053-1062.
Crossref
Crossref
Ayalew Tefferi & James W Vardiman. (2007) The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Current Opinion in Hematology 14:2, pages 115-122.
Crossref
Crossref
N Gangat, A P Wolanskyj, R F McClure, C-Y Li, S Schwager, W Wu & A Tefferi. (2006) Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 21:2, pages 270-276.
Crossref
Crossref
Alessandro M. Vannucchi & Tiziano Barbui. (2007) Thrombocytosis and Thrombosis. Hematology 2007:1, pages 363-370.
Crossref
Crossref
Jürgen Thiele & Hans M. Kvasnicka. (2007) Myelofibrosis – What’s in a Name?. Pathobiology 74:2, pages 89-96.
Crossref
Crossref
Hans Michael Kvasnicka & Jürgen Thiele. (2007) Classification of Ph-Negative Chronic Myeloproliferative Disorders – Morphology as the Yardstick of Classification. Pathobiology 74:2, pages 63-71.
Crossref
Crossref
Craig M. Kessler & Jan Jacques Michiels. 2007. Consultative Hemostasis and Thrombosis. Consultative Hemostasis and Thrombosis
295
318
.
. (2006) Current Awareness in Hematological Oncology. Hematological Oncology 24:2, pages 89-96.
Crossref
Crossref
Ayalew Tefferi. (2006) Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era. Hematology 2006:1, pages 240-245.
Crossref
Crossref